Description: Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women's health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others. The Company's principal product candidates are Zoptrex (zoptarelin doxorubicin) and Macrilen (macimorelin) in oncology and endocrinology. The Company focuses on its product candidates Zoptrex and Macrilen, which are in Phase III clinical development, and on a luteinizing hormone-releasing hormone (LHRH)-disorazol Z conjugate (AEZS-138), which is in pre-clinical development in oncology and is available for partnering. The Company's direct and indirect subsidiaries include AEZS GmbH, Zentaris IVF GmbH and Aeterna Zentaris, Inc.
Home Page: www.zentaris.com
AEZS Technical Analysis
315 Sigma Drive
Summerville,
SC
29486
United States
Phone:
843 900 3223
Officers
| Name | Title |
|---|---|
| Dr. Klaus Paulini Ph.D. | Pres, CEO & Exec. Director |
| Dr. Nicola Ammer M.D. | Chief Medical Officer & Sr. VP of Clinical Devel. |
| Dr. Matthias Gerlach | Sr. VP Manufacturing & Supply Chain |
| Mr. Giuliano La Fratta | Sr. VP of Fin. & CFO |
| Dr. Michael Teifel | Sr. VP of Non-Clinical Devel. & Chief Scientific Officer |
| Dr. Eckhard G. Guenther Ph.D. | Sr. VP of Bus. Devel. & Alliance Management and MD of AEZS Germany |
| Ms. Amélie Métivier | Assistant Sec. |
Exchange: TO
Country: CA
Currency: Canadian Dollar (C$)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.3518 |
| Price-to-Sales TTM: | 5.3154 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |